# Maxion Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maxion-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.maxiontherapeutics.com/
- Total disclosed funding: $166M
- Latest round: Series A (Mar 21, 2025)
- Investors on record: 8

## About

Founded in 2020 by its CEO, John McCafferty, and CSO, Aneesh Karatt-Vellatt, and based in Cambridge, UK, Maxion Therapeutics Ltd., operates as a biotechnology platform that develops therapeutic drugs for chronic pain, autoimmunity, and cardiovascular disease. In March 2025, Maxion Therapeutics Ltd. raised GBP 58 million in Series A funding led by new investor General Catalyst Partners, with participation from other new investors British Patient Capital, Solasta Ventures, and Eli Lilly & Company. Returning investor LifeArc, Monograph Capital Partners, and Business Growth Fund.

 The company offers therapies addressing chronic pain, autoimmunity, and cardiovascular diseases via the ion channel and GPCR-driven diseases. The company KnotBody® Technology by fusing naturally occurring cysteine-rich miniproteins (Knottins) into antibody binding loops in ion channel and GPCR drug discovery, offering superior selectivity compared to small-molecule drugs. 

The company plans to use the March 2025 funding to transform into a clinical-stage biotech company.

## Funding rounds

- Series A, Mar 21, 2025, $75M — General Catalyst Partners, Lilly Ventures, British Patient Capital, Solasta Ventures
- Series A, Mar 7, 2025, $75M — General Catalyst Partners, BGF Investment Management, Eli Lilly & Company, British Patient Capital, Solasta Ventures, Monograph Capital, LifeArc
- Series A, Feb 1, 2023, $16M — BGF Investment Management, Monograph Capital, LifeArc

## Investors

- BGF Investment Management (https://capitalatlas.ai/funds/bgf-investment-management) — Series A
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A
- LifeArc (https://capitalatlas.ai/funds/lifearc) — Series A
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A
- Eli Lilly & Company — Series A
- British Patient Capital — Series A
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series A
- Lilly Ventures (https://capitalatlas.ai/funds/lilly-ventures) — Series A